PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Blood Component Removal”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 37 records · Page 2Linked to original sources
PubMed1991

Hematopoietic stem cell processing and storage.

The techniques to collect, process, and store HSC in anticipation of transplantation are now widely available. Important unresolved issues revolve around the as yet imperfect identification and classification of totipotential progenitors. However, much progress has been and will continue to be made despite this limitation. Research priorities of present and future stem cell processing laboratories should include: 1. Optimization of liquid (nonfrozen) storage techniques. This will permit more complex cell-specific manipulations, such as T-lymphocyte subset selection, isolation of CD34+ populations, treatment in vitro with growth factors, gene transfer experiments, and long-range transport of HSC, to be performed while preserving HSC integrity. 2. A better understanding of the regulation and kinetics of peripheral blood and umbilical cord HSC, to allow optimum collection procedures that do not require marrow harvesting. 3. An intensive study into the optimum conditions of collection, processing, and storage of megakaryocytic progenitors to decrease the long platelet-transfusion dependency of the myeloablated patient. 4. A search for a simple in vitro correlate of engraftment potential of a stem cell preparation. This will greatly improve the quality control functions of the laboratory as well as contribute to better patient selection for transplantation.

Animals↗
PubMed2004

[Checking of blood product in hospital].

Delivery of blood products includes: checking of the parcel destination address, checking of the parcel itself and of its contents. Preserving the blood product in a depot imposes an agreement of storage between the hospital and the French national blood service to be established. In addition, authorisation of storage from the administrative head of department is required. The "Etablissement francais du sang" must be partner of the process.

Blood Component Removal↗
PubMed2004

Blood component fractionation: manual versus automatic procedures.

Over the last few years, quality system requirements have been introduced for blood components. The necessary compliance with standard productions will have a considerable impact on Blood Banks. The introduction of automated methods is the most satisfactory means to meet these requirements for blood component preparation. A new device has been developed to automate the fractionation of blood into components. We evaluated the efficacy of this instrument as compared to manual methods. A total of 218 units of blood have been collected, into several different commercial blood bag systems (77 into standard quadruple bag systems, 141 into bag systems with integrated in line filters), and used to evaluate the universality of the instrument. Whole blood units were processed using the Top/Top system and the Compomat G4 (Fresenius HemoCare). A separate program protocol was developed for each kind of bag. Use of the Compomat G4 resulted in a statistically significant (p<0.001) increase of the hemoglobin in filtered red cell concentrates (RCC) in comparison with the manual procedure, and a similar trend, even not statistically significant, has been observed for filtered RCC. Regardless of bag systems, we were able to observe a statistically significant increase of platelets in the platelet concentrates (PCs), when comparing automatic versus manual procedure. The automated procedure has been shown to be fast, and easy for the operators. This device reliably produces acceptable blood components, and has been shown adaptable to use with different blood bag systems.

Automation↗
PubMed2004

Universal leukodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions.

BACKGROUND: Universal leukodepletion of blood components to prevent acute non-hemolytic transfusion reactions (NHTRs) is still a subject of debate. PATIENTS AND METHODS: Transfusion-associated NHTRs observed at our hospital in the last 6 years were retrospectively analyzed. Buffy-coat depleted red blood cells (bc-RBCs), and if indicated, leucodepleted post-storage (ld-RBCs) were initially used. In April 1997, universal leukodepletion was implemented at our hospital, and thereafter only prestorage ld-RBCs were used. All platelet concentrates transfused during this time were prestorage filtered single-donor apheresis platelets (SDAPs). RESULTS: A total of 163,090 blood products were transfused from April 1995 to April 2001 (bc-RBC: n=34,040 units; ld-RBC: n=66,967; SDAP: n=14,516; FFP: n=47,567). The number of post-transfusion febrile NHTRs occurring with each blood product was 65 (0.19%) for bc-RBCs, 8 (0.16%) for post-storage ld-RBCs, 16 (0.03%) for prestorage ld-RBCs, 16 (0.11%) for SDAPs, and 10 (0.02%) for FFP. Allergic reactions (n=116) were most frequently observed after SDAP transfusion (0.32%) and occurred at a similarly low rate after transfusion of all other blood components (0.03-0.08%). CONCLUSION: In conclusion, acute NHTRs rarely occur after the use of leukodepleted blood components. Prestorage appears to be more effective than post-storage leukodepletion in preventing febrile reactions following a blood transfusion.

Blood Component Removal↗
PubMed2005

Circulation and distribution of 111-In-oxine-labeled autologous baboon platelet aggregates and buffy coat.

BACKGROUND: Although it is known that RBC concentrates may contain buffy coat and platelet concentrates may contain platelet aggregates, the circulation and distribution of these materials in the blood products have never been reported. STUDY DESIGN AND METHODS: Baboon platelets were labeled with 111-In-oxine, aggregated with ADP and autotransfused without a filter. Baboon buffy coat was stored at 4 degrees C, labeled with 111-In-oxine and autotransfused without a filter. The circulation of the radiolabeled platelets and buffy coat was measured and the distribution of the buffy coat and platelet aggregates was measured by external scanning of the baboon using a gamma camera. The effects of the infusion of aggregated platelets, buffy coat, and gelatin on the plasma fibronectin level also were evaluated. RESULTS: The 111-In-oxine labeled platelet aggregates were initially sequestered in the lungs and released into the peripheral blood during the next 3h, during which time the cell associated radioactivity increased by about 25%. Following the autotransfusion of 111-In-oxine labeled buffy coat, the 111-In-oxine radioactivity over the lungs increased, but decreased during the 60-min post-transfusion period as the radioactivity over the liver increased. Cell-associated radioactivity increased by about 10% over the 3-h post-transfusion period. Fibronectin levels decreased by 3% following the autotransfusion of platelet aggregates, by 10% after the autotransfusion of buffy coat and by 50% after the infusion of gelatin. CONCLUSIONS: 111-In-oxine radioactivity in the platelet aggregates and buffy coat was initially sequestered in the lungs, and 10-25% of the 111-In-oxine cell-associated radioactivity was released into the circulation during the 24-h post-transfusion period.

Animals↗